MBX Biosciences Inc (MBX)

Currency in USD
29.78
-0.44(-1.46%)
Closed·
30.19+0.41(+1.38%)
·
Earnings results expected in 15 days
MBX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
29.7632.03
52 wk Range
9.4344.89
Key Statistics
Prev. Close
30.22
Open
30.18
Day's Range
29.76-32.03
52 wk Range
9.43-44.89
Volume
442.1K
Average Volume (3m)
543.45K
1-Year Change
170.3901%
Book Value / Share
8.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MBX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
62.55
Upside
+110.03%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

MBX Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
0 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 62.55
(+110.03% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Buy50.00+67.90%-MaintainApr 23, 2026
Stifel
Buy50.00+67.90%-MaintainApr 13, 2026
Citizens
Buy76.00+155.20%-MaintainMar 13, 2026
Truist Securities
Buy50.00+67.90%-MaintainMar 12, 2026
Truist Securities
Buy50.00+67.90%-MaintainMar 12, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-0.49 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MBX Income Statement

Compare MBX to Peers and Sector

Metrics to compare
MBX
Peers
Sector
Relationship
P/E Ratio
−16.3x−6.7x−0.5x
PEG Ratio
−0.28−0.110.00
Price/Book
3.8x2.1x2.6x
Price / LTM Sales
-2.1x3.2x
Upside (Analyst Target)
121.6%174.7%48.1%
Fair Value Upside
Unlock10.0%6.6%Unlock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.39M19.77%279.66M
Other Institutional Investors
60.31M80.23%1.80B
Public Companies & Retail Investors
0.000.00%0.00
Total
69.7M100.00%2.08B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Frazier Life Sciences Management, LP14.00%6,652,013198,097
Frazier Life Sciences X, L.P.10.99%5,219,440155,435

People Also Watch

24.23
JBIO
-0.70%
21.67
BCAX
+0.42%
25.18
ALMS
+1.98%
1.960
CMPX
+10.73%
29.26
MLYS
+9.79%

FAQ

What Is the MBX Biosciences (MBX) Stock Price Today?

The MBX Biosciences stock price today is 29.78 USD.

What Stock Exchange Does MBX Biosciences Trade On?

MBX Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for MBX Biosciences?

The stock symbol for MBX Biosciences is "MBX."

What Is the MBX Biosciences Market Cap?

As of today, MBX Biosciences market cap is 1.42B USD.

What Is MBX Biosciences's Earnings Per Share (TTM)?

The MBX Biosciences EPS (TTM) is -2.38.

When Is the Next MBX Biosciences Earnings Date?

MBX Biosciences will release its next earnings report on May 18, 2026.

From a Technical Analysis Perspective, Is MBX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has MBX Biosciences Stock Split?

MBX Biosciences has split 0 times.

How Many Employees Does MBX Biosciences Have?

MBX Biosciences has 63 employees.

What is the current trading status of MBX Biosciences (MBX)?

As of May 03, 2026, MBX Biosciences (MBX) is trading at a price of 29.78 USD, with a previous close of 30.22 USD. The stock has fluctuated within a day range of 29.76 USD to 32.03 USD, while its 52-week range spans from 9.43 USD to 44.89 USD.

What Is MBX Biosciences (MBX) Price Target According to Analysts?

The average 12-month price target for MBX Biosciences is 62.55 USD, with a high estimate of 88 USD and a low estimate of 20 USD. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +110.03% Upside potential.

What Is the MBX After Hours Price?

MBX's last after hours stock price is 30.19 USD, the stock has decreased by 0.41, or 1.38%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.